SCHEMBL2932325

SCHEMBL2932325

O=C(Nc1n[nH]c2nc(-c3cccc(C(F)(F)F)c3)c(-c3ccnc(NCC4CC4)n3)cc12)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
VCP P55072 8/20 0.47
MAPK13 O15264 5/20 0.41
MAPK12 P53778 5/20 0.41
MAPK11 Q15759 5/20 0.41
MAPK14 Q16539 5/20 0.41
GSK3A P49840 2/20 0.41
GSK3B P49841 2/20 0.41
CDK2 P24941 1/20 0.40
MAPK9 P45984 1/20 0.40
MGLL Q99685 1/20 0.38
GRIN2B Q13224 1/20 0.37
CRHR1 P34998 2/20 0.37
EPHB4 P54760 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2924940 0.86 GSK3A (0.41) VCPMAPK13MAPK12MAPK11MAPK14
SCHEMBL2932651 0.84 MAPK14 (0.40) MAPK13MAPK12MAPK11MAPK14GSK3A
SCHEMBL2932911 0.84 EGFR (0.41) MAPK13MAPK12MAPK11MAPK14GSK3A
SCHEMBL29652640 0.76 MAPK13 (0.47) VCPMAPK13MAPK12MAPK11MAPK14
SCHEMBL2930500 0.76 MAPK13 (0.47) VCPMAPK13MAPK12MAPK11MAPK14
SCHEMBL2929634 0.74 MAPK13 (0.46) VCPMAPK13MAPK12MAPK11MAPK14
SCHEMBL2929738 0.71 MAPK14 (0.47) MAPK13MAPK12MAPK11MAPK14GSK3B
SCHEMBL1385324 0.70 TOP2A (0.43) MAPK13MAPK12MAPK11MAPK14GSK3A
SCHEMBL1387050 0.67 MAP4K4 (0.46) VCPMAPK13MAPK12MAPK11MAPK14
SCHEMBL2926498 0.67 VCP (0.53) VCPGSK3AGSK3BCDK2MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 VCP 2603/4885MAPK13 36/4885MAPK12 38/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 VCP 2291/4885MAPK13 37/4885MAPK12 39/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 VCP 2291/4885MAPK13 37/4885MAPK12 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.